{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T01:39:52Z","timestamp":1795225192506,"version":"4.10.3"},"reference-count":38,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jacadv.2024.100996","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T15:25:05Z","timestamp":1717601105000},"page":"100996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"P1","title":["Significance of Persistent Inflammation in Patients With Chronic Coronary Syndrome"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7098-9406","authenticated-orcid":false,"given":"Hiroshi","family":"Iwata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Miyauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Iimuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9079-1103","authenticated-orcid":false,"given":"Yukio","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Hibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takefui","family":"Hiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Hokimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisao","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Daida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryozo","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2024.100996_bib1","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2024.100996_bib2","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(02)08351-4","article-title":"Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up","volume":"359","author":"Group","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2024.100996_bib3","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacadv.2024.100996_bib4","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacadv.2024.100996_bib5","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacadv.2024.100996_bib6","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacadv.2024.100996_bib7","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2024.100996_bib8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2024.100996_bib9","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.005460","article-title":"More- versus less-intensive lipid-lowering therapy","volume":"12","author":"Toyota","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacadv.2024.100996_bib10","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"420","author":"Libby","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.jacadv.2024.100996_bib11","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacadv.2024.100996_bib12","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacadv.2024.100996_bib13","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacadv.2024.100996_bib14","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacadv.2024.100996_bib15","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1161\/CIRCULATIONAHA.117.032615","article-title":"High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD): a randomized superiority trial","volume":"137","author":"Taguchi","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2024.100996_bib16","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1093\/eurheartj\/ehy217","article-title":"Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA)","volume":"39","author":"Budoff","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2024.100996_bib17","first-page":"341","article-title":"Comparison of high-sensitivity C-reactive protein serum assay results obtained using Dade-Behring BNII nephelometer and ortho vitros FS 5.1 clinical analyzer in respect of CRP-related risk assessment of chronic metabolic diseases","volume":"54","author":"Kusnierz-Cabala","year":"2008","journal-title":"Clin Lab"},{"key":"10.1016\/j.jacadv.2024.100996_bib18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1536\/ihj.17-557","article-title":"Rationale and design of randomized evaluation of aggressive or moderate lipid lowering therapy with pitavastatin in coronary artery disease (REAL-CAD) trial","volume":"59","author":"Miyauchi","year":"2018","journal-title":"Int Heart J"},{"key":"10.1016\/j.jacadv.2024.100996_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/sjos.12167","article-title":"A\u00a0proportional hazards Regression model for the sub-distribution with covariates adjusted censoring weight for competing risks data","volume":"43","author":"He","year":"2016","journal-title":"Scand Stat Theory Appl"},{"key":"10.1016\/j.jacadv.2024.100996_bib20","doi-asserted-by":"crossref","first-page":"846","DOI":"10.5551\/jat.GL2017","article-title":"Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017","volume":"25","author":"Kinoshita","year":"2018","journal-title":"J\u00a0Atheroscler Thromb"},{"key":"10.1016\/j.jacadv.2024.100996_bib21","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/bcp.12905","article-title":"Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms","volume":"81","author":"Sahebkar","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacadv.2024.100996_bib22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.118.034032","article-title":"Inflammatory and cholesterol risk in the FOURIER trial","volume":"138","author":"Bohula","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2024.100996_bib23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fcvm.2019.00016","article-title":"Targeting residual inflammatory risk: a shifting paradigm for atherosclerotic disease","volume":"6","author":"Aday","year":"2019","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacadv.2024.100996_bib24","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1093\/eurheartj\/ehy633","article-title":"Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions","volume":"39","author":"Kalkman","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2024.100996_bib25","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1016\/j.jacc.2018.06.082","article-title":"Clinician's guide to reducing inflammation to reduce atherothrombotic risk: JACC review topic of the week","volume":"72","author":"Ridker","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2024.100996_bib26","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jacc.2005.04.051","article-title":"Race and gender differences in C-reactive protein levels","volume":"46","author":"Khera","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2024.100996_bib27","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIRCULATIONAHA.106.613570","article-title":"C-reactive protein as a risk predictor: do race\/ethnicity and gender make a difference?","volume":"114","author":"Albert","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2024.100996_bib28","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1161\/ATVBAHA.107.157164","article-title":"High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese: the Hisayama study","volume":"28","author":"Arima","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacadv.2024.100996_bib29","article-title":"hsCRP level and the risk of death or recurrent cardiovascular events in patients with myocardial infarction: a healthcare-based study","volume":"8","author":"Carrero","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacadv.2024.100996_bib30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1161\/CIRCULATIONAHA.110.985150","article-title":"Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling","volume":"124","author":"Antoniades","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2024.100996_bib31","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/j.1476-5381.2009.00612.x","article-title":"Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase\/signal transducers and activators of transcription pathways in human vascular endothelial cells","volume":"159","author":"Jougasaki","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jacadv.2024.100996_bib32","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2567.2010.03269.x","article-title":"Simvastatin induces Foxp3+ T regulatory cells by modulation of transforming growth factor-beta signal\u00a0transduction","volume":"130","author":"Kim","year":"2010","journal-title":"Immunology"},{"key":"10.1016\/j.jacadv.2024.100996_bib33","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.atherosclerosis.2017.06.010","article-title":"Ezetimibe and simvastatin combination inhibits and reverses the pro-inflammatory and pro-atherogenic effects of cream in obese patients","volume":"263","author":"Ghanim","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacadv.2024.100996_bib34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000357953","article-title":"Anti-inflammatory activity of ezetimibe by regulating NF-kappaB\/MAPK pathway in THP-1 macrophages","volume":"93","author":"Qin","year":"2014","journal-title":"Pharmacology"},{"key":"10.1016\/j.jacadv.2024.100996_bib35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacadv.2024.100996_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114519","article-title":"Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers","volume":"9","author":"Arsenault","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jacadv.2024.100996_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022348","article-title":"Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels: a systematic review and meta-analysis of randomised controlled trials","volume":"8","author":"Cao","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacadv.2024.100996_bib38","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41569-021-00629-x","article-title":"Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis","volume":"19","author":"Chen","year":"2022","journal-title":"Nat Rev Cardiol"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X24001856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X24001856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T09:30:09Z","timestamp":1722159009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X24001856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2772963X24001856"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2024.100996","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Significance of Persistent Inflammation in Patients With Chronic Coronary Syndrome","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2024.100996","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"100996"}}